Alphatec Spine, a wholly owned subsidiary of Alphatec Holdings, is a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spine disorders, primarily focused on the aging spine.
Under the agreement, which is effective immediately and has a three year term with the option to renew, RTI will process allograft implants for use in spine made from assembled cortical allograft.
RTI chairman and CEO Brian Hutchison said through the agreement they will be able to help even more patients with biologic solutions in spine.
Alphatec Spine president and CEO Dirk Kuyper said the relationship will allow them to continue to meet and exceed customers’ expectations.
